Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035165 · ClinicalTrials.gov registry record · Phase 2
EPO906 Therapy in Patients With Advanced Melanoma
A Phase 2 study of Melanoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 6
- Study locations
NCT00035165 is a Phase 2 study of Melanoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 51 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT00035165, a Phase 2 study of Melanoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause melanoma.
Conditions Studied
Interventions
- DRUG epothilone b
Study Locations (6)
Colorado
- University of Colorado - Aurora
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
New York
- Comprehensive Cancer Center@ Our Lady if Mercy Medical Center - The Bronx
North Carolina
- Duke University Medical Center - Durham
Oklahoma
- Oklahoma Oncology, Inc. - Tulsa
Pennsylvania
- UPMC Health Systems - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2002-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035165
The ClinicalTrials.gov registry entry for NCT00035165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which epothilone b is the first listed.
NCT00035165 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Colorado, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00035165 about?
NCT00035165 is a clinical study titled "EPO906 Therapy in Patients With Advanced Melanoma". This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause melanoma.
What is the current status of trial NCT00035165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2002-03.
What conditions does trial NCT00035165 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00035165?
The interventions under investigation include: epothilone b (DRUG).
Who is sponsoring clinical trial NCT00035165?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00035165 being conducted?
This trial has 6 study locations across Colorado, Florida, New York, North Carolina, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.